GlaxoSmithKline (GB:GSK) has released an update.
GlaxoSmithKline has reported success in phase III trials of depemokimab for severe asthma, meeting primary endpoints with significant reductions in asthma attacks over a year compared to placebo. This innovative biologic, administered only twice a year, could revolutionize treatment for millions with severe asthma by simplifying therapy regimens. Although depemokimab is not yet approved, its potential to change the management of severe asthma is being closely watched by GSK and the medical community.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
